Vor Biopharma (NYSE:VOR) Earns “Outperform” Rating from Wedbush

Vor Biopharma (NYSE:VOR)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a research note issued on Friday,RTT News reports. They currently have a $11.00 target price on the stock.

Several other equities research analysts have also recently commented on the company. JMP Securities reissued a “market outperform” rating and issued a $12.00 target price on shares of Vor Biopharma in a research note on Friday, September 6th. Barclays decreased their price objective on Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating for the company in a report on Wednesday, August 14th. Robert W. Baird dropped their target price on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday. Finally, HC Wainwright restated a “buy” rating and set a $17.50 price target on shares of Vor Biopharma in a research report on Friday. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vor Biopharma currently has a consensus rating of “Buy” and an average price target of $11.36.

Vor Biopharma Stock Performance

Shares of VOR stock traded up $0.12 on Friday, hitting $0.96. 781,468 shares of the stock traded hands, compared to its average volume of 504,849. The stock has a market capitalization of $65.53 million, a PE ratio of -0.55 and a beta of -0.40. The firm’s 50-day moving average price is $0.80 and its two-hundred day moving average price is $1.08. Vor Biopharma has a twelve month low of $0.63 and a twelve month high of $3.14.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, meeting the consensus estimate of ($0.41). On average, equities research analysts anticipate that Vor Biopharma will post -1.51 EPS for the current fiscal year.

Institutional Trading of Vor Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the business. Hsbc Holdings PLC grew its position in shares of Vor Biopharma by 177.0% during the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after buying an additional 31,333 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in Vor Biopharma during the second quarter worth $53,000. Acadian Asset Management LLC bought a new position in Vor Biopharma in the first quarter valued at about $126,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vor Biopharma during the second quarter worth about $63,000. Finally, Rosalind Advisors Inc. bought a new position in Vor Biopharma in the third quarter valued at approximately $54,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.